PARSIPPANY, N.J., July 14 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. announced today that it and certain of its officers have been named as defendants in purported shareholder class action lawsuits filed in the United States District Court for the District of Utah. The lawsuits allege that between August 2005 and May 2006, the defendants made misleading statements concerning the company’s market prospects for its proprietary drug, PREOS.
The company believes neither the law nor the facts support the claims made in these complaints. As a result, the company believes that the claims are without merit and will defend against them vigorously.
About NPS Pharmaceuticals
NPS discovers, develops and commercializes small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of clinical development backed by a strong discovery research effort. Additional information is available on the company’s website, http://www.npsp.com .
Cautionary Statement for the Purpose of the “Safe Harbor” Provisions of the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters set forth in this press release, including statements as to development and commercialization of the company’s products, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including, early stage of development; the timing of clinical trials; the dependence on collaborative and licensing agreements; approval and commercialization of our products and other risks detailed from time to time in the company’s SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2005, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2006. The company disclaims any intent or obligation to update these forward-looking statements.
NPS Pharmaceuticals, Inc.
CONTACT: Brandi Simpson, Sr. Director, Investor Relations of NPSPharmaceuticals, Inc., +1-801-583-4939
Web site: http://www.npsp.com/
Company News On-Call: http://www.prnewswire.com/comp/613587.html /
